Fenretinide Resistance in Ovarian Tumor Cells
Author Information
Author(s): Appierto V, Cavadini E, Pergolizzi R, Cleris L, Lotan R, Canevari S, Formelli F
Primary Institution: Department of Experimental Oncology, Istituto Nazionale Tumori, 20133 Milan, Italy
Hypothesis
The efficacy of fenretinide against ovarian tumours may be limited by induction of resistance.
Conclusion
Acquired resistance to fenretinide in ovarian tumor cells is associated with reduced drug accumulation and changes in marker expression.
Supporting Evidence
- The A2780 cell line became 10-fold more resistant to fenretinide after exposure to increasing concentrations.
- A2780/HPR cells showed a 3-fold reduction in colony-forming ability in agar compared to parental cells.
- The development of HPR resistance was associated with increased levels of retinoic acid receptor β (RARβ) mRNA and protein.
Takeaway
This study found that ovarian cancer cells can become resistant to a drug called fenretinide, making it less effective. This resistance happens because the cells don't take in the drug as well as they should.
Methodology
The study involved exposing the human ovarian carcinoma cell line A2780 to increasing concentrations of fenretinide and assessing changes in drug resistance and marker expression.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website